Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073502 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer
A Phase 2 study, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00073502 is a Phase 2 study that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 43 participants.
The verdict
NCT00073502, a Phase 2 study, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
Interventions
- DRUG OSI-7904L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2003-10 |
| Est. Completion | 2003-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073502
The ClinicalTrials.gov registry entry for NCT00073502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSI Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OSI-7904L is the first listed.
NCT00073502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073502 about?
NCT00073502 is a clinical study titled "Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer". Multi-center, open-label, non-randomized Phase II study to evaluate the efficacy and safety of OSI-7904L in gastric and GEJ cancers. Those patients who do not derive clinical benefit after two cycles may be switched to a commonly used combination regimen.
What is the current status of trial NCT00073502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2003-10. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00073502?
The interventions under investigation include: OSI-7904L (DRUG).
Who is sponsoring clinical trial NCT00073502?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.